TNFSF11 and osteoporosis: In addition, denosumab, an osteoporosis medication approved by the U.S Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is a human monoclonal antibody that targets RANKL, inhibiting RANKL/RANK interaction and consequently disrupting osteoclast formation.